MedNews Week Keynote - GI Oncology Update: Cholangiocarcinoma - Dr. James Cleary

Cholangiocarcinomas are bile duct cancers with a 17% 5-year survival rate that significantly decreases with further metastasis. Join us as we discuss the latest developments in Cholangiocarcinoma with Keynote Speaker and International Authority, Dr. James Cleary– Director of Clinical Research in the Division of GI Oncology at Dana-Farber Cancer Institute. Career Highlights Global Authority & Clinical Innovator in Gastrointestinal Cancers Internationally-renowned researcher who has directed many late phase clinical trials Among the first to: show the importance of RTK fusions in microsatellite-stable colorectal cancer & characterize mechanisms of resistance. evaluate the efficacy of Binimetinib in NRAS mutated cancers. identify FGFR2 INDELs in cholangiocarcinoma patients. Recipient of the Ellen and Stephen Fine Award for Outstanding Teaching in Cancer Medicine Leader of: GI Oncology Network and Collaborative Conference Scientific Program Committee, Colorectal and Anal Cancer Track. Member of: American Association for Cancer Research Sarcoma Medical Oncology Faculty Search Committee- DFCI Center for Cancer therapeutics and Innovation (CCTI) Medical Oncology Faculty Search Committee. Accomplished Keynote Speaker and author of more than 50 peer-reviewed manuscripts, book chapters, posters, and abstracts in such publications as New England Journal of Medicine, Journal of Clinical Oncology, Cancer Discovery, JAMA, Nature Reviews Cancer and much more.